Idorsia Ltd (LON:0RQE)
1.084
-0.050 (-4.39%)
At close: Apr 17, 2025
Idorsia Revenue
In the year 2024, Idorsia had annual revenue of 112.51M CHF, down -26.17%. Idorsia had revenue of 59.90M in the quarter ending December 31, 2024, with 178.42% growth.
Revenue
112.51M CHF
Revenue Growth
-26.17%
P/S Ratio
2.35
Revenue / Employee
173.09K CHF
Employees
650
Market Cap
233.43M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |